# CrestecBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crestecbio

- Industry: Biotechnology
- Headquarters: Tsukuba, Japan
- Website: www.crestecbio.com
- Total disclosed funding: $1.6M
- Latest round: Seed (Jun 2, 2026)
- Investors on record: 5

## About

Founded in 2021 and based in Tsukuba, Japan, CrestecBio Inc. operates as a company that develops polymer pharmaceuticals for neuroprotection and organ protection, with CTB211 as its lead program for ischemic stroke.

In June 2026, CrestecBio Inc. raised JPY 250 million in seed funding from UntroD Capital, Japan Science and Technology Agency, KSP, and Newsight Tech Angels.

CrestecBio Inc. focuses on developing innovative polymer pharmaceuticals aimed at protecting the brain and organs. Their core product, CTB211, is a polymer micelle formulation that incorporates the nitroxyl radical TEMPO, enhancing its biological half-life from 15 seconds to 60 minutes. This product is designed to effectively eliminate reactive oxygen species in various central nervous system cells, providing neuroprotective effects, with applications in treating ischemic strokes and other conditions. The company targets markets in Japan and the United States, with potential extensions into Europe and Asia, catering to healthcare providers, research institutions, and pharmaceutical partners.

CrestecBio Inc. generates revenue through partnerships with healthcare institutions and pharmaceutical companies interested in CTB211. The company engages in B2B transactions under contractual agreements, which may include volume pricing for large-scale purchases or research collaborations. Revenue structures may also involve licensing agreements, where partners pay for rights to use proprietary technology in clinical settings, or direct sales to hospitals and research facilities. As CTB211 proceeds through clinical trials, strategic alliances are expected to bolster revenue as the company delivers its therapeutic solutions globally.

As of June 2026, the company plans to initiate clinical trials for CTB211, expand its pipeline, strengthen development partnerships, and advance polymer drug applications across oxidative stress related diseases.

## Funding rounds

- Seed, Jun 2, 2026, $0.6M — Japan Science and Technology Agency, KSP, UntroD Capital Japan, Newsight Tech Angels
- Seed, Dec 9, 2025, $1M — UntroD Capital

## Investors

- UntroD Capital — Seed
- Japan Science and Technology Agency — Seed
- KSP (https://capitalatlas.ai/funds/ksp) — Seed
- UntroD Capital Japan (https://capitalatlas.ai/funds/untrod-capital-japan) — Seed
- Newsight Tech Angels (https://capitalatlas.ai/funds/newsight-tech-angels) — Seed